{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:16:55Z","timestamp":1772817415908,"version":"3.50.1"},"reference-count":40,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The deficiency of methylthioadenosine phosphorylase (MTAP) in T-cell acute lymphoblastic leukemia (T-ALL) and other cancers, while constitutively expressed in normal cells, allows for selective therapy using L-alanosine, an inhibitor of de novo AMP synthesis. We demonstrate that MTAP- T-ALL cells obtained at relapse are as sensitive to L-alanosine toxicity as diagnosis samples. The therapeutic index of L-alanosine can be increased by the use of a MTAP substrate, which protects MTAP+ normal cells. Since MTAP substrates MTA and 5\u2032deoxyadenosine are prone to toxicities associated with adenosine, we synthesized and evaluated a potentially nontoxic MTAP substrate, 9-\u03b2-D-erythrofuranosyladenine (EFA). The cytotoxicity of EFA to hematopoietic progenitors erythroid burst-forming units (BFU-Es) and granulocyte-macrophage colony-forming units (CFU-GMs) was at least 26- to 41-fold less than that of MTA. In addition, EFA selectively rescued MTAP+ MOLT-4 cells from L-alanosine toxicity at 25 \u03bcM with negligible toxicity even at 100 \u03bcM. As for MTA, significant, albeit incomplete, rescue was achieved at 12.5 \u03bcM, but higher concentrations were toxic. EFA at 20 \u03bcM or less rescued primary MTAP+ T-ALL cells and normal lymphocytes from L-alanosine toxicity. Collectively, these data indicate that EFA is an effective agent for salvaging MTAP+ cells from L-alanosine toxicity and is superior to MTA due to lower cytotoxicity.<\/jats:p>","DOI":"10.1182\/blood-2005-06-2430","type":"journal-article","created":{"date-parts":[[2005,10,19]],"date-time":"2005-10-19T03:39:03Z","timestamp":1129693143000},"page":"898-903","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["EFA (9-\u03b2-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine"],"prefix":"10.1182","volume":"107","author":[{"given":"Ayse","family":"Batova","sequence":"first","affiliation":[{"name":"From the Departments of Pediatrics\/Hematology-Oncology and Medicine, University of California San Diego, San Diego, CA; and the Institute of Cellular and Organismic Biology and The Genomics Research Center, Academia Sinica, Taipei, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Cottam","sequence":"additional","affiliation":[{"name":"From the Departments of Pediatrics\/Hematology-Oncology and Medicine, University of California San Diego, San Diego, CA; and the Institute of Cellular and Organismic Biology and The Genomics Research Center, Academia Sinica, Taipei, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Yu","sequence":"additional","affiliation":[{"name":"From the Departments of Pediatrics\/Hematology-Oncology and Medicine, University of California San Diego, San Diego, CA; and the Institute of Cellular and Organismic Biology and The Genomics Research Center, Academia Sinica, Taipei, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell B.","family":"Diccianni","sequence":"additional","affiliation":[{"name":"From the Departments of Pediatrics\/Hematology-Oncology and Medicine, University of California San Diego, San Diego, CA; and the Institute of Cellular and Organismic Biology and The Genomics Research Center, Academia Sinica, Taipei, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos J.","family":"Carrera","sequence":"additional","affiliation":[{"name":"From the Departments of Pediatrics\/Hematology-Oncology and Medicine, University of California San Diego, San Diego, CA; and the Institute of Cellular and Organismic Biology and The Genomics Research Center, Academia Sinica, Taipei, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice L.","family":"Yu","sequence":"additional","affiliation":[{"name":"From the Departments of Pediatrics\/Hematology-Oncology and Medicine, University of California San Diego, San Diego, CA; and the Institute of Cellular and Organismic Biology and The Genomics Research Center, Academia Sinica, Taipei, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111712520013500_REF1","doi-asserted-by":"crossref","unstructured":"Pegg AE, Williams-Ashman HG. Phosphate-stimulated breakdown of 5\u2032-methylthioadenosine by rat ventral prostate. Biochem J. 1969;115: 241-247.","DOI":"10.1042\/bj1150241"},{"key":"2019111712520013500_REF2","doi-asserted-by":"crossref","unstructured":"Backlund PS Jr, Smith RA. Methionine synthesis from 5\u2032-methylthioadenosine in rat liver. J Biol Chem. 1981;256: 1533-1535.","DOI":"10.1016\/S0021-9258(19)69835-2"},{"key":"2019111712520013500_REF3","doi-asserted-by":"crossref","unstructured":"Kamatani N, Nelsone-Rees WA, Carson DA. Selective killing of human malignant cell lines deficient in methylthioadenosine phosphorylase, a purine metabolic enzyme. Proc Natl Acad Sci U S A. 1981;78: 1219-1223.","DOI":"10.1073\/pnas.78.2.1219"},{"key":"2019111712520013500_","doi-asserted-by":"crossref","unstructured":"Toohey JI. Methylthioadenosine nucleoside phosphorylase deficiency in methylthio-dependent cancer cells. Biochem Biophys Res Comm. 1978;83: 27-35.","DOI":"10.1016\/0006-291X(78)90393-5"},{"key":"2019111712520013500_","doi-asserted-by":"crossref","unstructured":"Olopade OI, Pomykala HM, Hagos F, et al. Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21. Proc Natl Acad Sci U S A. 1995;92: 6489-6495.","DOI":"10.1073\/pnas.92.14.6489"},{"key":"2019111712520013500_","doi-asserted-by":"crossref","unstructured":"Nobori T, Takabayashi K, Tran P, Orvis L, Batova A, Yu AL. Genomic cloning of methylthioadenosine phosphorylase: a purine metabolic enzyme deficient in multiple cancers. Proc Natl Acad Sci U S A. 1996;93: 6203-6208.","DOI":"10.1073\/pnas.93.12.6203"},{"key":"2019111712520013500_","unstructured":"Jen J, Harper JW, Bigner SH, et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res. 1994;54: 6353-6358."},{"key":"2019111712520013500_","unstructured":"Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y. Frequent somatic mutation of the MTS1\/CDK41 (multiple tumor suppressor\/cyclin-dependent kinase 4 inhibitor) gene in esophogeal squamous cell carcinoma. Cancer Res. 1994;54: 3396-3397."},{"key":"2019111712520013500_REF9","doi-asserted-by":"crossref","unstructured":"Okuda T, Shurtleff SA, Valentine MB, et al. Frequent deletion of p16INK4a\/MTS1 and p15INK4b\/MTS2 in pediatric acute lymphoblastic leukemia. Blood. 1995;85: 2321-2330.","DOI":"10.1182\/blood.V85.9.2321.bloodjournal8592321"},{"key":"2019111712520013500_REF10","doi-asserted-by":"crossref","unstructured":"Batova A, Diccianni MB, Nobori T, et al. Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphocytic leukemia: strategies for enzyme-targeted therapy. Blood. 1996;88: 3083-3090.","DOI":"10.1182\/blood.V88.8.3083.bloodjournal8883083"},{"key":"2019111712520013500_REF11","unstructured":"Nobori T, Karras JG, Della Ragione F, Waltz TA, Chen PP, Carson DA. Absence of methylthioadenosine phosphorylase in human gliomas. Cancer. Res.1991;51: 3193-3197."},{"key":"2019111712520013500_REF12","unstructured":"Olopade OI, Buchhagen DL, Malik K, et al. Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res. 1993;53: 2410-2415."},{"key":"2019111712520013500_REF13","unstructured":"Nobori T, Szinai I, Amox D, et al. Methylthioadenosine phosphorylase deficiency in human non-small cell lung cancers. Cancer Res. 1993;53: 1098-1101."},{"key":"2019111712520013500_REF14","unstructured":"Fitchen JH, Riscoe MK, Dana BW, Lawrence HJ, Ferro AJ. Methylthioadenosine phosphorylase deficiency in human leukemias and solid tumors. Cancer Res. 1986;46: 5409-5412."},{"key":"2019111712520013500_REF15","doi-asserted-by":"crossref","unstructured":"Traweek ST, Riscoe MK, Ferro AJ, Braziel RM, Magenis RE, Fitchen JH. Methylthioadenosine phosphorylase deficiency in acute leukemia: pathologic, cytogenetic, and clinical features. Blood. 1988;71: 1568-1573.","DOI":"10.1182\/blood.V71.6.1568.1568"},{"key":"2019111712520013500_REF16","unstructured":"Illei PB, Rusch VW, Zakowski MF, Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res. 2003;9: 2108-2113."},{"key":"2019111712520013500_REF17","doi-asserted-by":"crossref","unstructured":"Kamatani N, Yu AL, Carson DA. Deficiency of methylthioadenosine phosphorylase in human leukemic cells in vivo. Blood. 1982;60: 1387-1391.","DOI":"10.1182\/blood.V60.6.1387.bloodjournal6061387"},{"key":"2019111712520013500_REF18","doi-asserted-by":"crossref","unstructured":"Sahota A, Webster DR, Potter CF, Simmonds AH, Rodgers AV, Gibson T. Methylthioadenosine phosphorylase activity in human erythrocytes. Clin Chim Acta. 1983;128: 283-290.","DOI":"10.1016\/0009-8981(83)90328-5"},{"key":"2019111712520013500_REF19","unstructured":"Yu J, Batova A, Shao L-E, Carrera CJ, Yu AL. Presence of methylthioadenosine phosphorylase (MTAP) in hematopoietic stem\/progenitor cells: its therapeutic implication for MTAP (-) malignancies. Clin Can Res. 1997;3: 4433-4438."},{"key":"2019111712520013500_REF20","unstructured":"Batova A, Diccianni MB, Omura-Minamisawa M, et al. Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro. Cancer Res. 1999;59: 1492-1497."},{"key":"2019111712520013500_REF21","doi-asserted-by":"crossref","unstructured":"Anandaraj SJ, Jayaram HN, Cooney DA, et al. Interaction of L-alanosine (NSC 153, 353) with enzymes metabolizing L-aspartic acid, L-glutamic acid and their amides. Biochem Pharmacol. 1980;29: 227-245.","DOI":"10.1016\/0006-2952(80)90333-0"},{"key":"2019111712520013500_","unstructured":"Tyagi AK, Cooney DA. Identification of the anti-metabolite of L-alanosine, L-alanosyl-5-amino-4-imidazolecarboxylic acid ribonucleotide, in tumors and assessment of its inhibition of adenylosuccinate synthetase. Cancer Res. 1980;40: 4390-4397."},{"key":"2019111712520013500_","doi-asserted-by":"crossref","unstructured":"Gale GR, Schmidt GB. Mode of action of alanosine. Biochem Pharmacol. 1968;17: 363-368.","DOI":"10.1016\/0006-2952(68)90246-3"},{"key":"2019111712520013500_REF24","doi-asserted-by":"crossref","unstructured":"Tyagi AK, Cooney DA. Biochemical pharmacology, metabolism, and mechanism of action of L-alanosine, a novel, natural antitumor agent. Adv Pharmacol Chemother. 1984;20: 69-121.","DOI":"10.1016\/S1054-3589(08)60265-3"},{"key":"2019111712520013500_REF25","doi-asserted-by":"crossref","unstructured":"Smith DS, King CS, Pearson E, Gittinger CK, Landret GE. Selective inhibition of nerve growth factor-stimulated protein kinases by K-252a and 5\u2032-S-methyladenosine in PC12 cells. J Neurochem. 1989;53: 800-806.","DOI":"10.1111\/j.1471-4159.1989.tb11776.x"},{"key":"2019111712520013500_","doi-asserted-by":"crossref","unstructured":"Naslund M, Klasterska I, Kolman A, Ehrenberg L. Mutagenic and comutagenic action of 5\u2032-deoxy-5\u2032-(methylthio)adenosine. Mutat Res. 1986;161: 1-7.","DOI":"10.1016\/0027-5107(86)90094-1"},{"key":"2019111712520013500_","doi-asserted-by":"crossref","unstructured":"Munshi R, Clanachan AS, Baer HP. 5\u2032-Deoxy-5\u2032-methylthioadenosine: a nucleoside which differentiates between adenosine receptor types. Biochem Pharmacol. 1988;37: 2085-2089.","DOI":"10.1016\/0006-2952(88)90560-6"},{"key":"2019111712520013500_","doi-asserted-by":"crossref","unstructured":"Law RE, Stimmel JB, Damore MA, Carter C, Clarke S, Wall R. Lipopolysaccharide-induced NF-kappa B activation in mouse 70Z\/3 pre-B lymphocytes is inhibited by mevinolin and 5\u2032-methylthioadenosine: roles of protein isoprenylation and carboxyl methylation reactions. Mol Cell Biol. 1992;12: 103-111.","DOI":"10.1128\/MCB.12.1.103"},{"key":"2019111712520013500_REF29","doi-asserted-by":"crossref","unstructured":"Hunting D, Henderson JF. Effects of 5\u2032-deoxyadenosine on phosphoribosyl pyrophosphate and purine nucleotide synthesis in Ehrlich ascites tumor cells in vitro. Biochem Pharmacol. 1978;27: 2163-2169.","DOI":"10.1016\/0006-2952(78)90290-3"},{"key":"2019111712520013500_REF30","doi-asserted-by":"crossref","unstructured":"Olsson RA, Khouri EM, Bedynek L Jr, McLean J. Coronary vasoactivity of adenosine in the conscious dog. Circ Res. 1979;45: 468-478.","DOI":"10.1161\/01.RES.45.4.468"},{"key":"2019111712520013500_REF31","doi-asserted-by":"crossref","unstructured":"Murray DH, Prokop J. Synthesis of tetrose nucleosides, I: adenine nucleosides of erythrose and threose. J Pharm Sci. 1967;56: 865-870.","DOI":"10.1002\/jps.2600560716"},{"key":"2019111712520013500_REF32","doi-asserted-by":"crossref","unstructured":"Yu J, Shao L-E, Vaughan J, Vale W, Yu AL. Characterization of the potentiation effect of activin on human erythroid colony formation in vitro. Blood. 1989;73: 952-960.","DOI":"10.1182\/blood.V73.4.952.952"},{"key":"2019111712520013500_REF33","unstructured":"Hori H, Tran P, Carrera CJ, et al. Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells. Cancer Res. 1996;56: 5653-5658."},{"key":"2019111712520013500_REF34","doi-asserted-by":"crossref","unstructured":"Smaaland R, Schanche JS, Kvinnsland S, Hostmark J, Ueland PM. Methylthioadenosine phosphorylase in human breast cancer. Breast Cancer Res Treat. 1987;9: 53-59.","DOI":"10.1007\/BF01806694"},{"key":"2019111712520013500_","doi-asserted-by":"crossref","unstructured":"Li W, Su D, Mizobuchi H, et al. Status of methylthioadenosine phosphorylase and its impact on cellular response to L-alanosine and methylmer-captopurine riboside in human soft tissue sarcoma cells. Oncol Res. 2004;14: 373-379.","DOI":"10.3727\/0965040041292332"},{"key":"2019111712520013500_REF36","doi-asserted-by":"crossref","unstructured":"Behrmann I, Wallner S, Komyod W, et al. Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma. Am J Pathol. 2003;163: 683-690.","DOI":"10.1016\/S0002-9440(10)63695-4"},{"key":"2019111712520013500_REF37","doi-asserted-by":"crossref","unstructured":"Efferth T, Gebhart E, Ross DD, Sauerbrey A. Identification of gene expression profiles predicting tumor cell response to L-alanosine. Biochem Pharmacol. 2003;66: 613-621.","DOI":"10.1016\/S0006-2952(03)00341-1"},{"key":"2019111712520013500_REF38","doi-asserted-by":"crossref","unstructured":"Bruns RF. Adenosine receptor activation in human fibroblasts: nucleoside agonist and antagonists. Can J Physiol Pharmacol. 1980;58: 673-691.","DOI":"10.1139\/y80-110"},{"key":"2019111712520013500_REF39","doi-asserted-by":"crossref","unstructured":"Siddiqi SM, Jacobson KA, Esker JL, et al. Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors. J Med Chem. 1995;38: 1174-1188.","DOI":"10.1021\/jm00007a014"},{"key":"2019111712520013500_REF40","unstructured":"Blay J, White TD, Hoskin DW. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res. 1997;57: 2602-2605."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/3\/898\/1281326\/zh800306000898.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/3\/898\/1281326\/zh800306000898.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T17:33:48Z","timestamp":1626629628000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/3\/898\/22150\/EFA-9%CE%B2Derythrofuranosyladenine-is-an-effective"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,1]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,2,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-06-2430","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,1]]}}}